L-type amino-acid transporter 1 (LAT1): A therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia

Leukemia

Volumn 29, Issue 6, 2015, Pages 1253-1266

  Rosilio, C ^a,b   Nebout, M ^a,b   Imbert, V ^a,b   Griessinger, E ^a,b   Neffati, Z ^a,b   Benadiba, J ^a,b,c   Hagenbeek, T ^d   Spits, H ^e   Reverso, J ^c   Ambrosetti, D ^c   Michiels, J F ^c   Bailly Maitre, B ^a   Endou, H ^f,g   Wempe, M F ^h   Peyron, J F ^a,b,c  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d GENENTECH INC   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f KYORIN UNIVERSITY   (Japan)

^g J Pharma Co   (Japan)

^h UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; ANTILEUKEMIC AGENT; ASPARAGINASE; BIM PROTEIN; BORTEZOMIB; CASPASE 3; CCAAT ENHANCER BINDING PROTEIN; CD98 ANTIGEN; CHAPERONIN 60; DEXAMETHASONE; DOXORUBICIN; FIREFLY LUCIFERASE; HEAT SHOCK PROTEIN 90; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; JPH 203; L TYPE AMINO ACID TRANSPORTER 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PUMA PROTEIN; RAPAMYCIN; UNCLASSIFIED DRUG; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOBLASTOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR CLONING; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; THYMOCYTE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOTION; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930571933     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.338     Document Type: Article

References (42)

1. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380-390.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
3. Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Curr Opin Hematol 2009; 16: 299-305.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
5. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
6. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 2010; 24: 13-21.
7. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-414.
8. Hagenbeek TJ, Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 2008; 22: 608-619.
9. Yanagida O, Kanai Y, Chairoungdua A, Kim D, Segawa H, Nii T et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochem Biophys Acta 2001; 1514: 291-302.
10. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005; 90: 233-238.
11. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: A clinicopathologic study. Clin Cancer Res 2007; 13: 6369-6378.
12. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 2009; 59: 7-18.
13. Wempe MF, Rice PJ, Lightner JW, Jutabha P, Hayashi M, Anzai N et al. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet 2012; 27: 155-161.
14. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 2010; 101: 173-179.
15. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002; 61: 729-737.
16. Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA 2005; 102: 355-360.
17. Hagenbeek TJ, Naspetti M, Malergue F, Garcon F, Nunes JA, Cleutjens KB et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J Exp Med 2004; 200: 883-894.
18. Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, Dombret H et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106: 274-286.
19. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25: 4812-4830.
20. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010; 9: 3470-3478.
21. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213.
22. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
23. Suraweera A, Munch C, Hanssum A, Bertolotti A. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell 2012; 48: 242-253.
24. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011; 13: 184-190.
25. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998; 12: 982-995.
26. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307: 935-939.
27. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081-1086.
28. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11: 381-389.
29. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11: 619-633.
30. Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell 2000; 6: 1355-1364.
31. Yanagisawa N, Ichinoe M, Mikami T, Nakada N, Hana K, Koizumi W et al. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. J Clin Pathol 2012; 65: 1019-1023.
32. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-492.
33. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012; 103: 382-389.
34. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 2011; 61: 281-289.
35. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N et al. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99: 2380-2386.
36. Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X et al. The paradox of the unfolded protein response in cancer. Anticancer Res 2013; 33: 4683-4694.
37. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol 2013; 14: 500-508.
38. Hayashi K, Jutabha P, Endou H, Sagara H, Anzai N. LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells. J Immunol 2013; 191: 4080-4085.
39. Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008; 453: 529-533.
40. Bulus N, Feral C, Pozzi A, Zent R. CD98 increases renal epithelial cell proliferation by activating MAPKs. PLoS One 2012; 7: e40026.
41. Boulter E, Estrach S, Errante A, Pons C, Cailleteau L, Tissot F et al. CD98hc (SLC3A2) regulation of skin homeostasis wanes with age. J Exp Med 2013; 210: 173-190.
42. Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett 2013; 336: 114-126.